|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Aspirin, cyclooxygenase inhibition and colorectal cancer显示文摘Colorectal cancer(CRC)is the third most common type of cancer worldwide.Screening measures are far from adequate and not widely available in resourcepoor settings.Primary prevention strategies therefore remain necessary to reduce the risk of developing CRC.Increasing evidence from epidemiological studies,randomized clinical trials and basic science supports the effectiveness of aspirin,as well as other non-steroidal anti-inflammatory drugs,for chemoprevention of several types of cancer,including CRC.This includes the prevention of adenoma recurrence and reduction of CRC incidence and mortality.The detectable benefit of daily low-dose aspirin(at least 75 mg),as used to prevent cardiovascular disease events,strongly suggests that its antiplatelet action is central to explaining its antitumor efficacy.Daily low-dose aspirin achieves complete and persistent inhibition of cyclooxygenase(COX)-1 in platelets(in pre-systemic circulation)while causing alimited and rapidly reversible inhibitory effect on COX-2and/or COX-1 expressed in nucleated cells.Aspirin has a short half-life in human circulation(about 20 minutes);nucleated cells have the ability to resynthesize acetylated COX isozymes within a few hours,while platelets do not.COX-independent mechanisms of aspirin have been suggested to explain its chemopreventive effects but this concept remains to be demonstrated in vivo at clinical doses. | Carlos Sostres Carla Jerusalen Gargallo Angel Lanas | 2014 | World Journal of Gastrointestinal Pharmacology and Therapeutics2014，5，1： | 8 |
| 2 | Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: Old question new insights显示文摘Previous reports clearly demonstrated that Helicobacter pylori(H.pylori)infection,nonsteroidal anti-inflammatory drugs(NSAID)or low dose aspirin(ASA)use significantly and independently increased the risk for the development of peptic ulcer disease.Today,the presence of H.pylori infection associated with low dose ASA and/or NSAID use in the same patient is becoming more frequent and therefore the potential interaction between these factors and the consequences of it has important implications.Whether NSAID intake in the presence of H.pylori infection may further increase the risk of peptic ulcer carried by the presence of only one risk factor is still a matter of debate.Studies on the interaction between the two risk factors yielded conflicting data and no consensus has been reached in the last years.In addition,the interaction between H.pylori infection and low-dose ASA remains even more controversial.In real clinical practice,we can find different clinical scenarios involving these three factors associated with the presence of different gastrointestinal and cardiovascular risk factors.These huge variety of possible combinations greatly hinder the decision making process of physicians. | Carlos Sostres Carla Jerusalen Gargallo Angel Lanas | 2014 | World Journal of Gastroenterology2014，20，28： | 8 |
| 3 | A graphical user -friendly interface for M CR -ALS:a new tool for multivariate curve resolution in MATLAB显示文摘 | Jaumot J Gargallo R Juan A D etal | 2005 | Chemometrics and Intelligent Laboratory Systems2005，76，1： | 1 |
| 4 | Technical note: A modified three-step in vitro procedure to determine intestinal digestion of proteins显示文摘 | Gargallo S Calsamiglia S Ferret A | 2006 | J Anim Sci2006，84，： | 1 |
| 5 | A systematic review on the effects of local antimicrobials as adjuncts to subgingival debridement, compared with subgingival debridement alone, in the treatment of chronic periodontitis显示文摘 | Paula Matesanz‐Pérez María García‐Gargallo Elena Figuero Antonio Bascones‐Martínez Mariano Sanz David Herrera | 2013 | J Clin Periodontol2013，，3： | 1 |
| 6 | Chronic lymphocytic leukemia developing in a patient with chronic myeloid leukemia: evidence of distinct lineage-associated genomic events 显示文摘 | GARGALLO P CACCHIONE R CHENA C | 2005 | Cancer Genct Cytogenet2005，161，1： | 1 |
| 7 | Balancing the risk and benefits of low-dose aspirin in clinical practice 显示文摘 | Casado-Arroyo R Gargallo C Lanas AA | 2012 | Best Pract Res Clin Gastroenterol2012，26，2： | 1 |
| 8 | Fluid and electrolyte disorders following surgery for brain tumors显示文摘 | Segura Matute S Balaguer Gargallo M Cambra Lasaosa FJ | 2007 | An Pediatr(Bare)2007，67，5： | 1 |
| 9 | Dental health inliver transplant patients显示文摘 | Diaz Ortiz ML Mieo Llorens JM Gargallo Albiol J | 2005 | Med Oral PatolOral Cir Bucal2005，10，1： | 1 |
| 10 | Balancing the risk and benefits of low-dose aspirin in clinical practice显示文摘 | Rubén Casado-Arroyo Carla Gargallo ángel Lanas Arbeloa | 2012 | Best Practice & Research Clinical Gastroenterology2012，，2： | 1 |
| 11 | Endosseous dental implant fractures an analysis of 21 cases 显示文摘 | Gargallo - Albiol J Satorres-Nieto M Puyuelo-Capablo JL | 2008 | Med Oral Patol Oral Cir Bucal2008，13，2： | 1 |
| 12 | Surface properties of inclusion complexes between a-cyclodextrin and poly(ethylene oxide)显示文摘 | Gargallo L Vargas D Leiva A | 2006 | Journal of Colloid and Interface Science2006，301，2： | 1 |
| 13 | Technical note:A modified three-step in vitro procedure to determine intestinal digestion of proteins显示文摘 | Gargallo S Calsamiglia S Ferret A | 2006 | Journal of Animal Science2006，84，8： | 1 |
| 14 | New coordination compounds of palladium ( II ) with iminodiacetic acid 显示文摘 | Castillo - Martos M Gargallo M F | 1977 | Transition Met Chem1977，2，： | 1 |
| 15 | Pharmacogenetics implementation in the clinics:information and guidelines for germline variants显示文摘The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice.An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided.These are PharmGKB single nucleotide polymorphism(SNP)-Drug Clinical Annotations with levels of evidence 1 or 2;the genetic information provided in the drug labels by the drug regulatory main agencies(Food and Drug Administration and European Medicines Agency,mainly);and the guidelines elaborated by international expert consortia(mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group).A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled. | Gladys Olivera Luis Sendra María JoséHerrero Pablo Berlanga Pablo Gargallo Yania Yáñez Andrea Urtasun Jaime Font de Mora Victoria Castel Adela Cañete Salvador FAliño | 2019 | Cancer Drug Resistance2019，2，1： | 1 |
| 16 | Fluid and electrolyte disorders following surgery for brain tumors显示文摘 | Balaguer Gargallo M Cambra Lasaosa FJ | 2007 | An Pediatr(Barc)2007，67，： | 1 |
| 17 | Antisense oligonucleotides increase the apoptotic effect of idarubicin in K562 cell line显示文摘 | Cuello T Gargallo P | 2000 | Medicina2000，60，1： | 1 |
| 18 | Technical note: a modified three-step in vitro procedure to determine intestinal digestion of proteins 显示文摘 | Gargallo S Calsamiglia S Ferret A | 2006 | Journal of Animal Science2006，84，： | 1 |
| 19 | Is NSAIDs-related gastrointestinal damage preventable?显示文摘 | Gargallo CJ Lanas A | 2013 | J Dig Dis2013，14，2： | 1 |
| 20 | Is NSAIDs-related gastrointestinal damage preventable?显示文摘 | Gargallo CJ Lamas A | 2013 | J Dig Dis2013，14，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员